Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quavonlimab - Merck Sharp & Dohme

Next Previous
Drug Profile

Quavonlimab - Merck Sharp & Dohme

Alternative Names: AK-107; MK-1308

Latest Information Update: 06 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer Merck Sharp & Dohme
  • Class Antineoplastics; Biological factors; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Non-small cell lung cancer
  • Phase I/II Malignant melanoma; Solid tumours

Most Recent Events

  • 17 Oct 2025 Merck Sharp & Dohme completes a phase I/II clinical trials in Malignant melanoma (Metastatic disease, Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable, Combination therapy) in Switzerland, Spain, South Africa, Italy, Israel, Australia, USA and France (IV) (NCT04700072)
  • 25 Aug 2025 Merck Sharp & Dohme Corp completes the phase I/II KEYNOTE-U02 trial for Malignant melanoma (Combination therapy, Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable) in USA, Switzerland, Australia, France, Germany, Israel, Italy, South Africa (IV) (NCT04305041) (EudraCT2019-003956-35)
  • 13 Jun 2025 Merck completes a phase II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease) in United Kingdom, Taiwan, Switzerland, Spain, South Africa, Singapore, Russia, Poland, Poland, South Korea, Japan, Japan, Italy, Italy, Ireland, Hong Kong, Canada, Australia, Australia, USA (IV) (NCT03516981)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top